These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 3103904)

  • 1. Buserelin treatment of advanced prostatic carcinoma. Long-term follow-up of antitumor responses and improved quality of life.
    Presant CA; Soloway MS; Klioze SS; Yakabow A; Presant SN; Mendez RG; Kennedy PS; Wyres MR; Naessig VL; Todd B
    Cancer; 1987 May; 59(10):1713-6. PubMed ID: 3103904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Buserelin as primary therapy in advanced prostatic carcinoma.
    Presant CA; Soloway MS; Klioze SS; Kosola JW; Yakabow AL; Mendez RG; Kennedy PS; Wyres MR; Naessig VL; Ford KS
    Cancer; 1985 Nov; 56(10):2416-9. PubMed ID: 3930064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of advanced prostatic carcinoma with a depot LH-RH analog (ICI 118630)].
    Grifoni R; Pierangeli T
    Minerva Urol Nefrol; 1989; 41(1):5-10. PubMed ID: 2527415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Buserelin treatment of advanced prostatic cancer: a phase II study.
    Veronesi A; Lo Re G; Dal Bo V; Magri MD; Della Valentina M; Talamini R; Merlo A; Francini M; Monfardini S
    Med Oncol Tumor Pharmacother; 1989; 6(4):255-7. PubMed ID: 2515400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long term follow-up of patients with advanced prostatic cancer treated with nasal buserelin.
    Falkson CI; Falkson G; Falkson HC
    Ann Oncol; 1991 Apr; 2(4):303-4. PubMed ID: 1907843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Buserelin in the treatment of prostatic cancer.
    Roila F
    Biomed Pharmacother; 1989; 43(4):279-85. PubMed ID: 2506941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A long term follow-up of patients with advanced prostatic cancer treated with buserelin.
    Waxman JH; Hendry WF; Whitfield HN; Oliver RT
    Prog Clin Biol Res; 1985; 185A():271-7. PubMed ID: 3929266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum prolactin levels in patients treated with a gonadotropin-releasing hormone analogue for adenocarcinoma of the prostate.
    Siegel YI; Korczak D; Lindner A
    Eur Urol; 1991; 19(1):16-8. PubMed ID: 1901042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of advanced prostatic cancer with buserelin, an analogue of gonadotrophin releasing hormone.
    Waxman JH; Wass JA; Hendry WF; Whitfield HN; Bary P; Besser GM; Malpas JS; Oliver RT
    Br J Urol; 1983 Dec; 55(6):737-42. PubMed ID: 6418264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [1st clinical results of the treatment of locally advanced prostatic cancer with a powerful LH-RH analog: buserelin acetate].
    Nagel R; Borgmann V; Al-Abadi H; Schmidt-Gollwitzer M
    J Urol (Paris); 1983; 89(9):669-76. PubMed ID: 6425419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Duration of testosterone suppression after a 9.45 mg implant of the GnRH-analogue buserelin in patients with localised carcinoma of the prostate a 12-month follow-up study.
    Pettersson B; Varenhorst E; Petas A; Sandow J
    Eur Urol; 2006 Sep; 50(3):483-9. PubMed ID: 16626856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term results with the Gn-RH analogue, buserelin, in metastatic prostate cancer.
    Maffezzini M; Villa E; Broglia L; Francesca F; Rigatti P
    Tumori; 1990 Feb; 76(1):66-8. PubMed ID: 2108517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advanced male breast cancer treatment with the LH-RH analogue buserelin alone or in combination with the antiandrogen flutamide.
    Doberauer C; Niederle N; Schmidt CG
    Cancer; 1988 Aug; 62(3):474-8. PubMed ID: 3134119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dramatic response of pulmonary metastasis from prostatic cancer to LH-RH agonist treatment.
    Heyman J; Leiter E
    Mt Sinai J Med; 1989 Mar; 56(2):108-10. PubMed ID: 2501670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical importance of prostatic measurements in follow-up of GnRH analogue-treated prostatic carcinoma patients.
    Matzkin H; Greenstein A; Braf Z
    Urology; 1990 Sep; 36(3):214-8. PubMed ID: 2118285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of a Dutch trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer and results of EORTC studies in prostatic cancer.
    Debruyne FM
    Am J Clin Oncol; 1988; 11 Suppl 1():S33-5. PubMed ID: 2968760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response of circulating gonadotropin levels to GnRH agonist treatment in prostatic cancer.
    Huhtaniemi I; Venho P; Jacobi G; Rannikko S
    J Androl; 1991; 12(1):46-53. PubMed ID: 1901309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acne conglobata responding to buserelin, a gonadotrophin-releasing hormone analogue.
    Waxman J; Rustin MH; Perry L; Kirby JD
    Br J Dermatol; 1983 Dec; 109(6):679-81. PubMed ID: 6228245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of prostatic cancer with LH-RH analogues.
    Borgmann V; Nagel R; Al-Abadi H; Schmidt-Gollwitzer M
    Prostate; 1983; 4(6):553-68. PubMed ID: 6415628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocrine and clinical evaluation of 107 patients with advanced prostatic carcinoma under long-term pernasal buserelin or intramuscular decapeptyl depot treatment.
    Jacobi GH; Wenderoth UK; Ehrenthal W; von Wallenberg H; Spindler HW; Hohenfellner R
    Am J Clin Oncol; 1988; 11 Suppl 1():S36-43. PubMed ID: 2968761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.